Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EU Funding for Clinical Trials of a Placental Malaria Vaccine

Published: Tuesday, March 05, 2013
Last Updated: Monday, March 04, 2013
Bookmark and Share
PlacMalVac project has received an FP7 EU grant.

PlacMalVac - a project coordinated by University of Copenhagen has received an FP7 EU grant, which will enable the first clinical trial of a VAR2CSA based vaccine to target malaria parasites infecting pregnant women.

The international consortium includes the Centre for Medical Parasitology (CMP) from University of Copenhagen (Denmark), ExpreS2ion Biotechnologies (Denmark), Institut de Recherche pour le Développement (France), European Vaccine Initiative (EVI, Germany), Université d'Abomey-Calavi (Benin), & University of Tübingen (Germany).

The clinical development program was initiated in 2012 with support from the Danish National Advanced Technology Foundation.

Professor Ali Salanti from the University of Copenhagen: “The funding from DNATF allowed us to commence a very ambitious and high risk vaccine development project, and in this project we managed to define and show proof of concept for the malaria vaccine and we are currently addressing manufacturability of the vaccine. The funding from EU FP7 will enable us to continue the development including upstream and downstream process development, GMP production, Phase Ia and Ib human clinical trials, as well as preparations for Phase II clinical trials."

Professor Thor G. Theander from the University of Copenhagen: “This will be the first clinical trial using the parasite antigens that cause severe disease syndromes. The vaccine attempts not to eliminate the infection but to eliminate the disease. At Centre for Medical Parasitology we are all thrilled to have this opportunity and it marks an intermediate highpoint of many years of committed research. If the vaccine is safe it will, however, require many years of continued international support before it can help pregnant women and their unborn children.”

Dr. Charlotte Dyring, CEO of ExpreS2ion Biotechnologies: “We are proud to be part of this significant effort in the fight against malaria. Our partnership with CMP has allowed us to leverage our Drosophila S2 cells-based protein expression platform capabilities to contribute to developing a potential vaccine for the millions of people impacted by placental malaria. Our platform is very well suited for production of complex and challenging antigens and has good scalability, which is one of the reasons why it is the choice of expression platform for this and other malaria projects."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
CNS Inflammation: A Pathway and Possible Drug Target
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!